Advertisement
Australia markets closed
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • AUD/USD

    0.6504
    +0.0015 (+0.23%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.75
    -0.61 (-0.73%)
     
  • GOLD

    2,327.70
    -14.40 (-0.61%)
     
  • Bitcoin AUD

    102,093.37
    +440.74 (+0.43%)
     
  • CMC Crypto 200

    1,434.79
    +10.69 (+0.75%)
     

Moderna, Xpeng and Uber rise premarket; State Street falls

By Peter Nurse

Investing.com -- Stocks in focus in premarket trade on Monday, April 17th. Please refresh for updates.

Merck (NYSE:MRK) stock fell 0.1% after the drugs giant announced Sunday plans to acquire Prometheus Biosciences (NASDAQ:RXDX), up 70%, for just short of $11 billion, building up its presence in immunology.

State Street (NYSE:STT) stock fell 8.4% after the financial services company reported disappointing first-quarter results, with earnings and revenue both below expectations.

Moderna (NASDAQ:MRNA) stock rose 2.5% after the company’s experimental mRNA cancer vaccine significantly cut the risk of death or recurrence of the most deadly skin cancer.

ADVERTISEMENT

Xpeng (NYSE:XPEV) stock rose 11% after the Chinese electric vehicle maker unveiled a new platform it developed in-house for making vehicles, which it said will reduce development and manufacturing costs.

Dell (NYSE:DELL) stock fell 2.1% after JPMorgan downgraded its stance on the tech giant to ‘neutral’ from ‘overweight’, while HP (NYSE:HPQ) stock rose 2.3% after the investment bank lifted it to ‘overweight’ from ‘neutral’.

Uber (NYSE:UBER) stock rose 1.2% after Jefferies called the ride-sharing firm a top pick in a note, expecting long-term earnings growth to drive its shares around 50% higher.

M&T Bank (NYSE:MTB) stock rose 3.1% after the lender beat expectations for first-quarter profit, as the Federal Reserve's rapid rate hikes to tame high inflation boosted its interest income.

Amneal Pharmaceuticals (NYSE:AMRX) stock rose 8.8% after the pharma company reported strong first-quarter revenue growth and reaffirmed its 2023 guidance.

Related Articles

Moderna, Xpeng and Uber rise premarket; State Street falls

US Supreme Court spurns Sanofi appeal to revive EpiPen suit against Viatris

Adobe to add generative AI tools into its video editing software